Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice

Journal of Agricultural and Food Chemistry

Volumn 55, Issue 26, 2007, Pages 10641-10648

  Han, Gi Cheol ^a   Ko, Sung Kwon ^b   Sung, Jong Hwan ^c   Chung, Sung Hyun ^a  

^a Kyung Hee University   (South Korea)

^b Semyung University   (South Korea)

^c IL HWA Co Ltd   (South Korea)

Author keywords

ATP sensitive K+ channel; Compound K; Diabetes; DNA microarray; Oral glucose tolerance test

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; GINSENOSIDE; GINSENOSIDE M1; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL LINE; DRUG EFFECT; GENE EXPRESSION; HAMSTER; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; MALE; METABOLISM; MOUSE; PANCREAS ISLET BETA CELL; PHYSIOLOGY; SECRETION;

ADIPOCYTES; ANIMALS; CELL LINE; CELLS, CULTURED; CRICETINAE; GENE EXPRESSION; GINSENOSIDES; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; KATP CHANNELS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR;

MUS; PANAX GINSENG;

EID: 38049083706     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf0722598     Document Type: Article

References (30)

1. Zimmet, P.; Alberti, K.; Shaw, G. J. Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787.
2. Goldstein, B. J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am. J. Cardiol. 2002, 90, 3-10.
3. Lebovitz, H. E.; Banerji, M. A. Treatment of insulin resistance in diabetes mellitus. Eur. J. Pharmacol. 2004, 19, 135-146.
4. Warren, R. E. The stepwise approach to the management of type 2 diabetes. Diabetes Res. Clin. Pract. 2004, 65S, S3-S8.
5. Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Eng. J. Med. 1993, 329, 977-986.
6. Attele, A. S.; Wu, J. A.; Yuan, C. S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58, 1685-1693.
7. Yokozawa, T.; Kobayashi, T.; Oura, H.; Kawashima, Y. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem. Pharm. Bull. 1985, 33, 869-872.
8. Attele, A. S.; Zhou, Y. P.; Xie, J. T.; Wu, J. A.; Zhang, L.; Dey, L.; Pugh, W.; Rue, P. A.; Polonsky, K. S.; Yuan, C. S. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002, 51, 1851-1858.
9. Vuksan, V.; Sievenpiper, J. L. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 149-160.
10. Lee, S. J.; Sung, J. H.; Lee, S. J.; Moon, C. K.; Lee, B. H. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett. 1999, 144, 39-43.
11. Lee, S. J.; Ko, W. G.; Kim, J. H.; Sung, J. H.; Moon, C. K.; Lee, B. H. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem. Pharmacol. 2000, 60, 677-685.
12. Lee, H. U.; Bae, E. A.; Han, M. J.; Kim, N. J.; Kim, D. H. Hepatoprotective effect of ginsenoside Rb1 and compound K on tert-butyl hydroperoxide-induced liver injury. Liver Int. 2005, 25, 1069-1073.
13. Trinder, P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J. Clin. Pathol. 1969, 22, 158-161.
14. Baginski, E. S.; Foa, P. P.; Zak, B. Determination of rat liver microsomal glucose-6-phosphatase activity: study of citrate and G-6-P inhibition. Anal. Biochem. 1967, 21, 201-207.
15. Hara, H.; Miwa, I.; Okuda, J. Inhibition of rat glucokinase by alloxan and ninhydrin. Chem. Pharm. Bull. 1986, 34, 4731-4737.
16. Lohr, G. W.; Waller, H. D. Glucose-6-phosphate dehydrogenase type bodense (a new enzyme variant). Klin. Wochenschr. 1971, 49, 1058-1062.
17. Yang, Y. H.; Dudoit, S.; Luu, P.; Lin, D. M.; Peng, V.; Ngai, J.; Speed, T. P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002, 30, e15.
18. Winer, J.; Jung, C. K.; Shackel, I.; Williams, P. M. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 1999, 270, 41-49.
19. Matthews, D. R.; Hosker, J. P.; Rudenski, A. S.; Naylor, B. A.; Treacher, D. F.; Turner, R. L. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412-419.
20. Kolterman, O. G. The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics. Diabetes Metab. Rev. 1987, 3, 399-414.
21. da Tos, V.; Maran, A.; Vigili de Kreutzenberg, S.; Marchetto, S.; Tadiotto, F.; Bettio, M.; Marescotti, M. C.; Tiengo, A.; Del Prato, S. Mechanisms of acute and chronic hypoglycemic action of gliclazide. Acta Diabetol. 2000, 37, 201-206.
22. Seoane, J.; Barbera, A.; Telemaque-Potts, S.; Newgard, C. B.; Guinovart, J. J. Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats. J. Biol. Chem. 1999, 274, 31833-31838.
23. Barthel, A.; Schmoll, D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E685-692.
24. Mithieux, G.; Guignot, L.; Bordet, J. C.; Wiernsperger, N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 2002, 51, 139-143.
25. Gaskin, R. S.; Estwick, D.; Peddi, R. G6PD deficiency: its role in the high prevalence of hypertension and diabetes mellitus. Ethn. Dis. 2001, 11, 749-754.
26. Miwa, H. I.; Okuda, J. Inhibition of rat glucokinase by alloxan and ninhydrin. Chem. Pharm. Bull. 1986, 34, 4731-4737.
27. Havel, P. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 2002, 13, 51-59.
28. Lindsay, R. S.; Funahashi, T.; Hanson, R. L.; Matsuzawa, Y.; Tanaka, S.; Tataranni, P. A.; Knowler, W. C.; Krakoff, J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360, 57-58.
29. Fu, Y.; Luo, N.; Klein, R. L.; Garvey, W. T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 2005, 46, 1369-1379.
30. Ryder, J. W.; Kawano, Y.; Chibalin, A. V.; Rincon, J.; Tsao, T. S.; Stenbit, A. E.; Combatsiaris, T.; Yang, J.; Holman, G. D.; Charron, M. J.; Zierath, J. R. In vitro analysis of the glucose-transport system in GLUT4-null skeletal muscle. Biochem. J. 1999, 342, 321-328.